National Rare Diseases Registry System of China and Related Cohort Studies: Vision and Roadmap

Human Gene Therapy

Volumn 29, Issue 2, 2018, Pages 128-135

  Feng, Shi ^a   Liu, Shuang ^a   Zhu, Chong ^b,c   Gong, Mengchun ^a,b   Zhu, Yicheng ^b,d   Zhang, Shuyang ^b,d  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b National Rare Diseases Registry System of China   (China)

^c Digital China Health Technologies Corporation Ltd   (China)

^d PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

cohort study; genomics; medical informatics; patient registry; rare diseases

Indexed keywords

ORPHAN DRUG;

ACCURACY; ARTICLE; CHINA; DISEASE REGISTRY; GENETIC DATABASE; GENOMICS; INFORMATION TECHNOLOGY; KNOWLEDGE BASE; PATIENT CARE; PRACTICE GUIDELINE; RARE DISEASE; STANDARDIZATION; COHORT ANALYSIS; GENETICS; HUMAN; REGISTER; TRANSLATIONAL RESEARCH; TRENDS;

CHINA; COHORT STUDIES; HUMANS; RARE DISEASES; REGISTRIES; TRANSLATIONAL MEDICAL RESEARCH;

EID: 85042150829     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2017.215     Document Type: Article

References (44)

1. Tiwari J. Navigating through orphan medicinal product regulations in EU and US - similarities and differences. Regul Toxicol Pharmacol 2015;71:63-67.
2. Angelis A, Tordrup D, Kanavos P. Socio-economic burden of rare diseases: a systematic review of cost of illness evidence. Health Policy 2015;119:964-979.
3. Tasdemir E, Magestro M, Griner BP, et al. Prevalence-based measurement of the economic burden of rare diseases: case review to determine the annual cost of acromegaly in France. Value Health 2014;17:A527.
4. Lacaze P, Millis N, Fookes M, et al. Rare disease registries: a call to action. Intern Med J 2017;47: 1075-1079.
5. Cram DS, Zhou D. Next generation sequencing: coping with rare genetic diseases in China. Intractable Rare Dis Res 2016;5:140-144.
6. Chen K, Yao L, Liu Z. Towards government-funded special biomedical research programs to combat rare diseases in China. Biosci Trends 2015;9:88-90.
7. Gong S, Wang Y, Pan X, et al. The availability and affordability of orphan drugs for rare diseases in China. Orphanet J Rare Dis 2016;11:20.
8. Rath A, Olry A, Dhombres F, et al. Representation of rare diseases in health information systems: the Orphanet approach to serve a wide range of end users. Hum Mutat 2012;33:803-808.
9. Boycott KM, Vanstone MR, Bulman DE et al. Raredisease genetics in the era of next-generation sequencing: discovery to translation. Nat Rev Genet 2013;14:681-691.
10. Kremer LS, Bader DM, Mertes C, et al. Genetic diagnosis of Mendelian disorders via RNA sequencing. Nat Commun 2017;8:15824.
11. Suhre K, Gieger C. Genetic variation in metabolic phenotypes: study designs and applications. Nat Rev Genet 2012;13:759-769.
12. Berg JS, Adams M, Nassar N, et al. An informatics approach to analyzing the incidentalome. Genet Med 2013;15:36-44.
13. Song P, Gao J, Inagaki Y, et al. Rare diseases, orphan drugs, and their regulation in Asia: current status and future perspectives. Intractable Rare Dis Res 2012;1:3-9.
14. Cui Y, Han J. A proposed definition of rare diseases for China: from the perspective of return on investment in new orphan drugs. Orphanet J Rare Dis 2015;10:28.
15. Pariser AR, Gahl WA. Important role of translational science in rare disease innovation, discovery, and drug development. J Gen Intern Med 2014; 29:S804-807.
16. Fagnan DE, Gromatzky AA, Stein RM, et al. Financing drug discovery for orphan diseases. Drug Discov Today 2014;19:533-538.
17. Mariz S, Reese JH, Westermark K, et al. Worldwide collaboration for orphan drug designation. Nat Rev Drug Discov 2016;15:440-441.
18. Forrest CB, Bartek RJ, Rubinstein Y, et al. The case for a global rare-diseases registry. Lancet 2011;377:1057-1059.
19. Golubnitschaja O, Kinkorova J, Costigliola V. Predictive, preventive and personalised medicine as the hardcore of "Horizon 2020": EPMA position paper. The EPMA J 2014;5:6.
20. Lochmuller H, Le Cam Y, Jonker AH, et al. "IRDiRC Recognized Resources": a new mechanism to support scientists to conduct efficient, highquality research for rare diseases. Eur J Hum Genet 2017;25:162-165.
21. Maaroufi M, Choquet R, Landais P, et al. Towards data integration automation for the French rare disease registry. AMIA Annu Symp Proc 2015; 2015:880-885.
22. Roy AJ, Van den Bergh P, Van Damme P, et al. Early stages of building a rare disease registry, methods and 2010 data from the Belgian Neuromuscular Disease Registry (BNMDR). Acta Neurol Belg 2015;115:97-104.
23. Lau CT, Kan A, Shek N, et al. Is congenital pulmonary airway malformation really a rare disease?. Result of a prospective registry with universal antenatal screening program. Pediatr Surg Int 2017;33:105-108.
24. Tattersfield AE, Glassberg MK. Lymphangioleiomyomatosis: a national registry for a rare disease. Am J Respir Crit Care Med 2006;173:2-4.
25. Nagel G, Ü nal H, Rosenbohm A, et al. Implementation of a population-based epidemiological rare disease registry: study protocol of the amyotrophic lateral sclerosis (ALS) - registry Swabia. BMC Neurol 2013;13:22.
26. Lewis J, Snyder M, Hyatt-Knorr H. Marking 15 years of the Genetic and Rare Diseases Information Center. Transl Sci Rare Dis 2017;2:77-88.
27. Hansson MG, Lochmuller H, Riess O, et al. The risk of re-identification versus the need to identify individuals in rare disease research. Eur J Hum Genet 2016;24:1553-1558.
28. Groza T, Kohler S, Moldenhauer D, et al. The human phenotype ontology: semantic unification of common and rare disease. Am J Hum Genet 2015;97:111-124.
29. de Lusignan S, Chan T, Jones S. Large complex terminologies: more coding choice, but harder to find data - reflections on introduction of SNOMED CT (Systematized Nomenclature of Medicine - Clinical Terms) as an NHS standard. Inform Prim Care 2011;19:3-5.
30. Gabetta M, Larizza C, Bellazzi R. A Unified Medical Language System (UMLS) based system for Literature-Based Discovery in medicine. Stud Health Technol Inform 2013;192:412-416.
31. Kohler S, Vasilevsky NA, Engelstad M, et al. The human phenotype ontology in 2017. Nucl Acids Res 2017;45:D865-D876.
32. NRDRS. Integration of Chinese Human Phenotype Ontology into National Rare Diseases Registry System of China. www.nrdrs.org/app/rare/repositorychpo. html (last accessed February 6, 2018).
33. Svenstrup D, Jorgensen HL, Winther O. Rare disease diagnosis: a review of web search, social media and large-scale data-mining approaches. Rare Dis 2015;3:e1083145.
34. Pavan S, Rommel K, Mateo Marquina ME, et al. Clinical practice guidelines for rare diseases: the Orphanet database. PLoS One 2017;12: e0170365.
35. Frey LJ, Bernstam EV, Denny JC. Precision medicine informatics. J Am Med Inform Assoc 2016; 23:668-670.
36. Bernstam EV, Tenenbaum JD, Kuperman GJ. Preserving an integrated view of informatics. J Am Med Inform Assoc 2014;21:e178-179.
37. Ohno-Machado L. Informatics research to enable clinically relevant, personalized genomic medicine. J Am Med Inform Assoc 2012;19:149-150.
38. Wang X, Wang E, Marincola FM. Translational medicine is developing in China: a new venue for collaboration. J Transl Med 2011;9:3.
39. Groft SC. Rare diseases research: expanding collaborative translational research opportunities. Chest 2013;144:16-23.
40. Foldvari A, Szy I, Sandor J, et al. [Diagnostic delay of rare diseases in Europe and in Hungary]. Orv Hetil 2012;153:1185-1190.
41. Anderson M, Elliott EJ, Zurynski YA. Australian families living with rare disease: experiences of diagnosis, health services use and needs for psychosocial support. Orphanet J Rare Dis 2013; 8:22.
42. Kole A, Faurisson F. Rare diseases social epidemiology: analysis of inequalities. Adv Exp Med Biol 2010;686:223-250.
43. Nie S, Chen G, Cao X, et al. Cerebrotendinous xanthomatosis: a comprehensive review of pathogenesis, clinical manifestations, diagnosis, and management. Orphanet J Rare Dis 2014;9: 179.
44. Horng HC, Teng SW, Huang BS et al. Primary fallopian tube cancer: domestic data and up-todate review. Taiwan J Obstet Gynecol 2014;53: 287-292.